Clemastine Fumarate

DRUG7 trials

Conditions

Brain Injury, Fetus and NeonateClinically Isolated Syndrome, CNS DemyelinatingDemyelinating DiseasesDemyelination; Corpus CallosumDepressionHealthy SubjectsInternuclear OphthalmoplegiaMultiple Sclerosis

Early Phase 1

Clemastine Fumarate for Alcohol Use Disorder

Active, not recruitingJPRN-jRCTs041220020

Kishi Taroalcohol dependence or alcohol use disorder Alcohol use disorder

Start: 2022-06-20Target: 5Updated: 2026-06-29

Phase 1

Effect of Clemastine Fumarate on Color Vision in Healthy Controls

CompletedNCT02613091

University of California, San FranciscoHealthy Subjects

Start: 2016-04-30Updated: 2016-11-03

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

RecruitingNCT05359653

University of California, San FranciscoMultiple Sclerosis Benign, Multiple Sclerosis Brain Lesion, Multiple Sclerosis, Chronic Progressive +4

Start: 2023-08-01End: 2027-06-01Target: 74Updated: 2026-07-02

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Not yet recruitingNCT06065670

University of California, San FranciscoClinically Isolated Syndrome, CNS Demyelinating, Demyelinating Diseases, Demyelination; Corpus Callosum +2

Start: 2026-09-15End: 2028-10-30Target: 44Updated: 2026-03-11

Neonatal White Matter Injury Trial (WRAP)

RecruitingNCT07688746

Bridget LaMonica Ostrem, M.D., Ph.D.Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia +2

Start: 2026-07-26End: 2031-07-01Target: 24Updated: 2026-07-28

Phase 2

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

RecruitingNCT06591091

University of Illinois at ChicagoDepression

Start: 2025-12-10End: 2026-12-01Target: 80Updated: 2026-06-30

Phase 3

Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis

TerminatedNCT05338450

Amsterdam UMC, location VUmcInternuclear Ophthalmoplegia, Multiple Sclerosis

Start: 2022-08-30End: 2025-08-15Updated: 2026-05-06

Related Papers

Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: a randomised controlled trial protocol (RESTORE)

BMJ Open2024-01-016 citations